Literature DB >> 7448105

The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy.

F D Juma, H J Rogers, J R Trounce.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7448105      PMCID： PMC1430090          DOI： 10.1111/j.1365-2125.1980.tb01768.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  17 in total

1.  The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide.

Authors:  H T Mouridsen; O Faber; L Skovsted
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

2.  Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.

Authors:  N Brock
Journal:  Cancer Treat Rep       Date:  1976-04

3.  Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.

Authors:  R F Struck; M C Kirk; M H Witt; W R Laster
Journal:  Biomed Mass Spectrom       Date:  1975-02

4.  Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat.

Authors:  J L Cohen; J Y Jao
Journal:  J Pharmacol Exp Ther       Date:  1970-08       Impact factor: 4.030

5.  Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.

Authors:  T A Connors; P J Cox; P B Farmer; A B Foster; M Jarman
Journal:  Biochem Pharmacol       Date:  1974-01-01       Impact factor: 5.858

6.  A biologically active metabolite of cyclophosphamide.

Authors:  M Colvin; C A Padgett; C Fenselau
Journal:  Cancer Res       Date:  1973-04       Impact factor: 12.701

7.  Clinical pharmacology of cyclophosphamide.

Authors:  C M Bagley; F W Bostick; V T DeVita
Journal:  Cancer Res       Date:  1973-02       Impact factor: 12.701

8.  Alkylating properties of phosphoramide mustard.

Authors:  M Colvin; R B Brundrett; M N Kan; I Jardine; C Fenselau
Journal:  Cancer Res       Date:  1976-03       Impact factor: 12.701

9.  Clinical toxicologic study of cyclohexylamine salt of N,N-bis(2-chlorethyl)phosphorodiamidic acid (NSC-69945; OMF-59).

Authors:  L Nathanson; T C Hall; A Rutenberg; R K Shadduck
Journal:  Cancer Chemother Rep       Date:  1967-02

10.  Pharmacokinetics of cyclophosphamide in man.

Authors:  J L Cohen; J Y Jao; W J Jusko
Journal:  Br J Pharmacol       Date:  1971-11       Impact factor: 8.739
View more
  13 in total

1.  Pharmacokinetics of cyclophosphamide in Kenyan Africans.

Authors:  F Juma; T Ogada
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

2.  Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.

Authors:  S Genka; J Deutsch; P L Stahle; U H Shetty; V John; C Robinson; S I Rapoport; N H Greig
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.

Authors:  G Powis; P Reece; D L Ahmann; J N Ingle
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of breast cancer.

Authors:  V J Wiebe; C C Benz; M W DeGregorio
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

5.  Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study.

Authors:  R N Harris; P J Basseches; P L Appel; A M Durski; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 8.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

9.  Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane.

Authors:  S Rosenow; K L Kooistra; G Powis; R A Van Dyke
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 10.  Intensive chemotherapy for solid tumours--current clinical applications.

Authors:  S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.